Hong Sang

Array ( [id] => 20302467 [patent_doc_number] => 12448445 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Transgene genetic tags and methods of use [patent_app_type] => utility [patent_app_number] => 17/812848 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 22 [patent_no_of_words] => 28401 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17812848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18725886 [patent_doc_number] => 20230340123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE [patent_app_type] => utility [patent_app_number] => 17/811586 [patent_app_country] => US [patent_app_date] => 2022-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17811586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945826 [patent_doc_number] => 20220332843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => ANTIBODIES AND METHOD OF PRODUCING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/808402 [patent_app_country] => US [patent_app_date] => 2022-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990213 [patent_doc_number] => 20220356250 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => CD47 ANTIGEN-BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 17/847020 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18197065 [patent_doc_number] => 20230050584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/841110 [patent_app_country] => US [patent_app_date] => 2022-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17841110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911412 [patent_doc_number] => 20220313807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => NOVEL PEPTIDES & COMBINATION OF PEPTIDES AS TARGETS OR ACTIVE INGREDIENTS FOR USE IN IMMUNOTHERAPY AGAINST AML & OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 17/838017 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938152 [patent_doc_number] => 20240033291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPRISING ANTI-MESOTHELIN SCFV, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/255814 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20716397 [patent_doc_number] => 12631639 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Methods for predicting therapeutic benefit of anti-CD19 therapy in patients [patent_app_type] => utility [patent_app_number] => 17/824266 [patent_app_country] => US [patent_app_date] => 2022-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 7850 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17824266 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389449 [patent_doc_number] => 20240279319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => ANTIBODY FOR IDENTIFYING PHOSPHORYLATION-SPECIFIC REACTIONS OF THREONINE AT POSITION 1010 OF NCAPG2, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/564010 [patent_app_country] => US [patent_app_date] => 2022-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9663 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18564010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865475 [patent_doc_number] => 20220288210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/746740 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18502 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18212830 [patent_doc_number] => 20230059094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => IMPROVED ANTAGONISTIC ANTI-HUMAN CD40 MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/742702 [patent_app_country] => US [patent_app_date] => 2022-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17742702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19281593 [patent_doc_number] => 20240218067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-04 [patent_title] => ANTI-SIGLEC COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/558112 [patent_app_country] => US [patent_app_date] => 2022-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790272 [patent_doc_number] => 20220249363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS [patent_app_type] => utility [patent_app_number] => 17/730149 [patent_app_country] => US [patent_app_date] => 2022-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17730149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17882766 [patent_doc_number] => 20220298243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT [patent_app_type] => utility [patent_app_number] => 17/715875 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25772 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17715875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186249 [patent_doc_number] => 20240165162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => METHODS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND COMBINATIONS WITH BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/550484 [patent_app_country] => US [patent_app_date] => 2022-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19644204 [patent_doc_number] => 20240418724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => MOLECULAR MARKER FOR DETERMINING VERY-EARLY-STAGE ONSET RISK OF GASTRIC CANCER AND EVALUATING PROGRESSION RISK OF PRE-CANCEROUS LESION OF GASTRIC CANCER, AND USE THEREOF IN DIAGNOSTIC KIT [patent_app_type] => utility [patent_app_number] => 18/704212 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18704212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246791 [patent_doc_number] => 20240197775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => COMPOSITIONS AND METHODS FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS [patent_app_type] => utility [patent_app_number] => 18/285649 [patent_app_country] => US [patent_app_date] => 2022-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18285649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945796 [patent_doc_number] => 20220332813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 17/712167 [patent_app_country] => US [patent_app_date] => 2022-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851932 [patent_doc_number] => 20220281974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/701436 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19058998 [patent_doc_number] => 11938192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Dosage regimes for the administration of an anti-CD19 ADC [patent_app_type] => utility [patent_app_number] => 17/699065 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 39799 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699065 [rel_patent_id] =>[rel_patent_doc_number] =>)